Paper29625879
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
Rimassa L and 29 others. Lancet Oncol, 2018. Cited by 301 papers, by iCite.
Cite this record
ConductScience Library. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Papers, record 29625879. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29625879
- Disease
- hepatocellular carcinoma478 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
- PubMed
- Publication types
- Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics24
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Proto-Oncogene Proteins c-met | Major topic |
| Pyrrolidinones | Major topic |
| Quinolines | Major topic |
| Administration, Oral | |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Americas | |
| Australia | |
| Double-Blind Method | |
| Drug Administration Schedule | |
| Europe | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| New Zealand | |
| Progression-Free Survival | |
| Time Factors | |
| Young Adult |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01755767 | Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 29625880 | Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target? | https://conductscience.org/library/papers/29625880 | PubMed |
| Comment in | 33437816 | The role of c-MET inhibitors in advanced hepatocellular carcinoma: now and future. | https://conductscience.org/library/papers/33437816 | PubMed |
Cited by207
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 301 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42652118 | Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: From Targeted Therapy and Combination Strategies to Emerging Therapies. | Biomedicines | 2026 | https://conductscience.org/library/papers/42652118 | PubMed |
| 42575887 | C-MET tyrosine kinase receptor: mechanisms, clinical applications and future perspectives in cancer therapy. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42575887 | PubMed |
| 42465003 | Prognostic value of salt-inducible kinase 2 expression in advanced hepatocellular carcinoma treated with sorafenib or lenvatinib: a propensity score-matched cohort study. | Am J Cancer Res | 2026 | https://conductscience.org/library/papers/42465003 | PubMed |
| 42270817 | Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement. | Nat Rev Clin Oncol | 2026 | https://conductscience.org/library/papers/42270817 | PubMed |
| 42222418 | Evaluating patient-reported outcomes in randomized controlled trials of targeted therapy and/or immunotherapy for liver cancer: a scoping review. | Front Oncol | 2026 | https://conductscience.org/library/papers/42222418 | PubMed |
| 42171920 | Inhibition of Aurora B induces senescence and potentiates immunotherapy in hepatocellular carcinoma. | Cell Oncol (Dordr) | 2026 | https://conductscience.org/library/papers/42171920 | PubMed |
| 41971838 | Molecular biology of targeting lymphangiogenesis in cancer: Therapeutic strategies and future promise. | Fundam Res | 2026 | https://conductscience.org/library/papers/41971838 | PubMed |
| 41931196 | Clinical Benefit and Global Regulation of Bispecific Antibody Drugs: A Cross-sectional Analysis. | BioDrugs | 2026 | https://conductscience.org/library/papers/41931196 | PubMed |
| 41921417 | Pattern of progression and post-progression survival following transarterial embolisation: An analysis of the TACE-2 and TACTICS trials. | JHEP Rep | 2026 | https://conductscience.org/library/papers/41921417 | PubMed |
| 41729336 | Distinct cMET inhibitors uncover pharmacological heterogeneity in SHH medulloblastoma cell lines. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41729336 | PubMed |
| 41598441 | Macrotrabecular-Massive Subtype Is Associated with a High Risk of the Recurrence of Hepatocellular Carcinoma. | J Clin Med | 2026 | https://conductscience.org/library/papers/41598441 | PubMed |
| 41445734 | Cancer-associated fibroblasts in cholangiocarcinoma: the central nexus of tumor-stroma crosstalk and therapeutic translation. | Front Immunol | 2025 | https://conductscience.org/library/papers/41445734 | PubMed |
| 41399945 | Response evaluation to systemic therapy in HCC: Current challenges and future perspectives. | Hepatology | 2026 | https://conductscience.org/library/papers/41399945 | PubMed |
| 40831037 | Tumor-based biomarkers and circulating tumor DNA for precision medicine in advanced hepatocellular carcinoma. | Clin Mol Hepatol | 2026 | https://conductscience.org/library/papers/40831037 | PubMed |
| 40749153 | Using Dose-Escalation and -Expansion Cohort Study as Pivotal Trial for Targeted Anticancer Drug Approval. | JCO Precis Oncol | 2025 | https://conductscience.org/library/papers/40749153 | PubMed |
| 40394703 | HHLA2 activates c-Met and identifies patients for targeted therapy in hepatocellular carcinoma. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40394703 | PubMed |
| 40344916 | Estrogen inhibits hepatocellular carcinoma progression dependent on HOXA11-AS/HOXA11. | Transl Oncol | 2025 | https://conductscience.org/library/papers/40344916 | PubMed |
| 40294893 | Unveiling TRIB3: A new mediator in MET-driven hepatocellular carcinoma progression: Editorial on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation". | Clin Mol Hepatol | 2026 | https://conductscience.org/library/papers/40294893 | PubMed |
| 40211872 | MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation. | Clin Mol Hepatol | 2025 | https://conductscience.org/library/papers/40211872 | PubMed |
| 40144682 | Future perspectives on immunotherapy for hepatocellular carcinoma. | Ther Adv Med Oncol | 2025 | https://conductscience.org/library/papers/40144682 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AFP | 174 | PubTator's text mining | https://conductscience.org/library/genes/174 | NCBI Gene |
| SLTM | 79811 | PubTator's text mining | https://conductscience.org/library/genes/79811 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| TIVANTINIB | CHEMBL2103882 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2103882 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29625879
GET https://conductscience.org/api/papers/v1/29625879/authors?page=2